Germ-Cell Tumors

  • Giannis Mountzios


Cancer originating from germ cells is a special disease, characterized by increased incidence in young men (18–40 years) and extremely good prognosis, even if it is diagnosed in advanced stages. The vast majority of these cancers are originated in the gonads (testicles), while a small percentage of germ cell tumors may appear in midline extragonadal locations that are embryologically developed from the central crest (epiphysis, mediastinum, retro peritoneum).


Germ cell tumors Testicular cancer Seminoma Non-seminoma Yolk sac Teratoma Embryonal carcinoma 


  1. 1.
    Einhorn LH (2002) Curing metastatic testicular ancer. Proc Natl Acad Sci U S A 99:4592–4595CrossRefGoogle Scholar
  2. 2.
    Bosl GJ, Motzer RJ (1997) Testicular germ-cell cancer. N Engl J Med 337:242–253CrossRefGoogle Scholar
  3. 3.
    Thomas GM, Rider WD, Dembo AJ et al (1982) Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. Int J Radiat Oncol Biol Phys 8:165CrossRefGoogle Scholar
  4. 4.
    Willan B, McGowan D (1985) Seminoma of the testis: a 22-year experience with radiation therapy. Int J Radiat Oncol Biol Phys 11:1769CrossRefGoogle Scholar
  5. 5.
    Classen J, Schmidberger H, Meisner C et al (2003) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21:1101CrossRefGoogle Scholar
  6. 6.
    Chung PW, Warde PR, Panzarella T et al (2003) Appropriate radiation volume for stage IIA/B testicular seminoma. Int J Radiat Oncol Biol Phys 56:746CrossRefGoogle Scholar
  7. 7.
    Warde P, Gospodarowicz M, Panzarella T et al (1998) Management of stage II seminoma. J Clin Oncol 16:290CrossRefGoogle Scholar
  8. 8.
    Loehrer PJ, Birch R, Williams SD et al (1987) Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 5:1212CrossRefGoogle Scholar
  9. 9.
    Rabbani F, Sheinfeld J, Farivar-Mohseni H et al (2001) Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 19:2020CrossRefGoogle Scholar
  10. 10.
    Kondagunta GV, Motzer RJ (2002) Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors. Semin Urol Oncol 20:239CrossRefGoogle Scholar
  11. 11.
    Williams SD, Stablein DM, Einhorn LH et al (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433CrossRefGoogle Scholar
  12. 12.
    Behnia M, Foster R, Einhorn LH (2000) Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. The Indiana University experience. Eur J Cancer 36:472CrossRefGoogle Scholar
  13. 13.
    Kondagunta G, Sheinfeld J, Mazumdar M et al (2004) Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 22:464CrossRefGoogle Scholar
  14. 14.
    Einhorn LH, Williams SD, Loehrer PJ et al (1989) Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 7:387. PubMedCrossRefGoogle Scholar
  15. 15.
    Bosl GJ, Geller NL, Bajorin D et al (1988) A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231. PubMedCrossRefGoogle Scholar
  16. 16.
    de Wit R, Stoter G, Kaye SB et al (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cooperative Group. J Clin Oncol 15:1837CrossRefGoogle Scholar
  17. 17.
    Loehrer PJ, Johnson DH, Elson P et al (1995) Importance of bleomycin in favorable prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 13:470CrossRefGoogle Scholar
  18. 18.
    Bajorin DF, Sarosdy MF, Pfister DG et al (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. J Clin Oncol 11:598CrossRefGoogle Scholar
  19. 19.
    Horwich A, Sleijfer D, Fossa S et al (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 15:1844CrossRefGoogle Scholar
  20. 20.
    Toner GC, Stockler MR, Boyer MJ et al (2001) Comparison of two standard chemotherapy regimens for good-prognosis germcell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357:739CrossRefGoogle Scholar
  21. 21.
    de Wit R, Stoter G, Sleijfer DT et al (1995) Four cycles of BEP versus an alternating regimen of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71:1311CrossRefGoogle Scholar
  22. 22.
    Nichols CR, Williams SD, Loehrer PJ et al (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163CrossRefGoogle Scholar
  23. 23.
    Kaye S, Mead G, Fossa S et al (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer Study. J Clin Oncol 16:692CrossRefGoogle Scholar
  24. 24.
    Nichols CR, Catalano P, Crawford ED et al (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors; an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16:1287CrossRefGoogle Scholar
  25. 25.
    Motzer RJ, Mazumdar M, Gulati SC et al (1993) Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828CrossRefGoogle Scholar
  26. 26.
    Motzer RJ, Mazumdar M, Bajorin DF et al (1997) High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in firstline therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15:2546CrossRefGoogle Scholar
  27. 27.
    Schmoll H-J, Kollmannsberger C, Metzner JT et al (2003) Long-term results of first-line sequential high-dose VIPchemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21:4083CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Giannis Mountzios
    • 1
  1. 1.Oncology DepartmentHenry Dunant Hospital CenterAthensGreece

Personalised recommendations